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Abstract 
Thiazolidinedione (1) was used as a key intermediate for the synthesis of many therapeutic anti-diabetic molecules. Thus, 
Thiazolidinedione (1) was refluxed with aromatic aldehydes and phenol derivatives to afforded aryldine derivative (3). 
Moreover, the stereochemistry for compound 3 was discussed using Hartree-Fock theory geometries,and have been 
optimized at HF with 6-311G level of theory. The HOMO-LUMO energy gap of studied systems has been discussed. The 
molecular docking simulations into the active site of ALR2 were performed, and showed that, the compound 3more 
suitable inhibitor against ALR2 and can used as anti- diabetic drug.  
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1. Introduction 
Diabetes mellitus (DM) is a common chronic, more than 220 million people worldwide suffer from DM, this figure is 
expected to increase by 2030 to 400 million cases [1,2].  Diabetic  complications (retinopathy,  neuropathy,  nephropathy  
or  cataract) are  serious  and  disabling pathologies  associated  with  DM[3]. Hyperglycemia is a typical condition of DM 
and plays a crucial role in the development and advancement of these complications, which arise from acute, and are thus 
largely responsible for the morbidity and mortality observed in these patients[1, 4-6]. 
Increasing flux of glucose through the polyol pathway, that occurs under hyperglycemic conditions in tissues 
possessing insulin-independent glucose transport is a well examined factor involved in the appearance and progression of 
such chronic complications[ 3,6-13]. Aldose reductase (EC 1.1. 1.21, ALR2) is the first enzyme of the polyol pathway, 
which responsible for reduction of glucose to sorbitol[14]. Glucose metabolism, specifically via ALR2 and the polyol 
pathway, is often linked to the development of chronic complications of diabetes mellitus. Therefore, ALR2 has been 
considered an attractive target enzyme, to develop drugs to control or prevent the progression of chronic diabetic 
complications, but remain many problems with toxicity and lack of targeted specificity towards the enzyme[11,13–16]. 
Many thiazolidinediones derivatives have been marketed for the treatment of non-insulin-dependent diabetes 
mellitus (NIDDM or type 2 diabetes) [17-,23], such as pioglitazone, rosiglitazone and troglitazone (Structure  1).  
Thiazolidinediones (TZDs), playing effective role in normalizing glucose metabolism associated with insulin resistance, so, 
TZDs are considering antidiabetic agents [21]. 
 
In view of the above mentioned, we discovery potent the synthetic thiazldinone derivatives  against 
diabetic II, though,  docking studies against ALR-2 to gain a new insight concerning possible binding modes of 
our compounds, which should also be useful to guide improved potency compounds against diabetic disease .  
2. Results and Discussion 
2.1 Chemistry 
2,4-Thiazolidinedione(1) was used as our starting material. The compound (1)was treatment with phenol in ethanolic 
AcONa toaffording unexpected product 5-(benzo[d][1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione (3) insteadof 5-
(benzo[d][1,3]dioxol-5-yl(4-hydroxyphenyl)-methyl)thiazolidine-2,4-dione (2;Scheme 1).  
 
                                                                                  ISSN 2321-807X 
2577 | P a g e                                                        A u g u s t  1 0 ,  2 0 1 4 
2.2 . Molecular Modeling Studies: 
2.2.1 Energy features 
Due to the presence double bond (represented *),the prepared compound 3is possible existence in two 
steroisomer forms E and Z (Scheme 2).The appearance NH fragment in thiazldinone ring, the prepared 
compoundhavetwo possible tautomerstructures (keto-form) form, which  represented in (Scheme 3), the geometrical 
optimization of both tautomerstructures represented in (Scheme 3). 
The molecular parameters and geometry optimization structures  were calculated  at  HF with 6-311 basis set 
using gaussian 09[24], andused to investigate the most stable steroisomerand tautomer form for compound3(Table 1, 
scheme 2 and 3).  
 
Due to the lowest calculated energy for TheE-Ketoform, so,it’s formis the most preferred structure for compound 
3 (Scheme2 and3, table1). 
 
The frontier molecular orbital’s (highest occupied molecular orbital, HOMO and lowest unoccupied molecular 
orbital, LUMO) are the most important orbitals in a molecule; these orbitals determine the way for the molecule interacts 
with other species. In general, the Eshowed lower HOMO energy thanZ forms. This data support that, theE- Keto form 
ishighest chemical reactivity and kinetic stability form [25-28]. 
The total dipole moment is considering important physical quantity, it reflects the ability interaction of the 
molecules with the surrounding environment, the E-Ketoare highest dipole value (~ 3.20 Debye), which increasing ability 
of interaction with the surrounding environments, and increase ability to binding with protein receptors, which increasing 
biological effects. The largest HOMO–LUMO gaps for E-Keto form, more electrophilcity (likely to involve reactions with a 
nucleophile) than other forms (Table 1).  
 
Table 1: The optimized calculations energies and reactivity descriptors of 3atHF with 6-311G basis set. 
Form E Eaq IP HF HOMO LUMO ΔG η S χ µ ω D 
3 
E-Keto -104553 -843344 8.721 -90.65 -8.740 -1.017 7.723 3.861 0.258 -4.878 4.878 3.081 3.202 
Z -104558 -831552 8.696 -96.11 -8.696 -0.971 7.725 3.862 0.258 -4.833 4.833 3.024 2.681 
E-enol -104557 -834877 8.740 -94.43 -8.721 -0.995 7.726 3.863 0.258 -4.858 4.858 3.054 2.391 
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E:The total energy (kcal/mol).,Eaq: aqueous energy (kcal/mol, heat of formation + strain energy),HOMO
: 
Highest 
Occupied Molecular Orbital (eV),LUMO: Lowest Occupied Molecular Orbital (eV),ΔG: difference between HOMO and 
LUMO energy levels(eV), η: Hardness(eV), S: Softness(eV), χ : Electronegativity (eV), µ: chemical potential(eV),  
ω:Electrophilicity (eV), D: dipole moment (Deby). 
2.2.2 Global and local reactivity descriptors: 
Hartree-Fock theory has been successful to recognize the chemical reactivity and site selectivity of the molecular 
systems, several global and local chemical reactivity descriptors for molecules have been defined, like S; softness 
(measures stability of molecules and chemical reactivity with direct proportional) [29] η;hardness (reciprocal of softness), 
µ; chemical potential, χ; electronegativity (strength atom for attracting electrons  to itself), ω;electrophilicity index 
(measuring  lowering energy  due  to  maximal  flowing electron between donor and acceptor), the Fukui function and the 
philicity [29-34].  
The E-Ketoformhas smallest hardness valueandhighestthe electrophilic capacity (Table 1), which indicating its 
more reactive molecularform and increasing susceptibly of nucleophilic attack on this molecule, this behavior may be 
explained by a large bond order for carbonyl group, exhibiting a stronger electron-attractor effect, that might be related 
with a localization of  electronic density on  its  atom (Figure  2). 
2.2.3. Optimized  Geometry 
the X-ray single crystal  for compound3is  not  available till now, since, in trying to achieve better insight of the 
molecular structure till the  crystal  structures  have  been  solved, the optimization geometry were performed in vacuo with 
HF quantum mechanical level using 6-311G set (Scheme 1and 2;Sup. Table 1  in supplementary material). 
The benzodioxole ring was arranged in coplanar position with 2,4-thiazldinon ring, and deviation angle from 
stereoisomer center about (~133°, 132° and 120°) for forms E-Keto , Z and E-enol, respectively, the bond 
lengthsofdoublebound (C5-C8)are nearly equal about (~1.3Å) for all forms (Sup. Figure (1and 2) and Sup. Table 1 in 
supplementary material). 
2.2.4. Electrostatic potentials (ESP) and Ionization potential (IP) mapped. 
The electrostatic potentials mapped (ESP) were drawn,which represents a balance between repulsive 
interactions of the nuclei (positively-charged) and attractive interactions for the electrons (negatively-charged). The colors 
toward red depict negative potential representing (high electron density area, strong attraction between the proton and the 
points on the molecular surface), while colors toward blue depict positive potential, and colors in between (orange, yellow, 
green) depict intermediate values of the potential. The most negative potential area located in CO  group in all 
forms,whicharranged byE-Keto>Z≥E-enol(figure 2).  
The local ionization potentials (IP) were drawn (figure 2), it indicates the proportional electron removal facility 
around the molecule (ionization), which measure the sensitivity of a molecular zone toward electrophilic attack (reactivity). 
The default program value (Fixed Value: (0.032e);   Medium   Resolution), is used for the surface mapped values of the 
(IP) (Figure 2).  The red color representing a region with highest likely attack with electrophile, and the blue regions likely 
attack with nucleophile (lowest electrophilic regions). The examination structures in (figure 2) showed that, the compound 
E-Keto formhave most electron rich around the surface of the molecule than other forms. This data suggest that, its 
formundergoing reaction, and occurring with higher conformation energy than other forms Zand E-enol. The examination 
distribution ideal charge for IP surface exhibits, the electrophile attack on surface of E-Keto form is favorable than other 
members, which given the red-yellow color distribution. 
 E-Keto Z E-enol 
ESP 
   
IP 
   
Figure. 2. The ESP and IP surfaces for most stable stereoisomer and most stable tautomer structure of3 with HF /6-311G 
calculations. 
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2.2.5. ADMET factorsprofiling:  
Oral bioavailability playing an important role for the development of bioactive molecules as therapeutic agents. 
Many potential therapeutic agents fail to reach the clinic, because of their ADMET (absorption, distribution, metabolism, 
elimination and toxic) factors. Therefore, a computational study for prediction of ADMET properties of the molecules were 
performed for reference drugs and its compounds 3, by the determination of topological polar surface area (TPSA), a 
calculated percent absorption (% ABS) which was estimated by Zhao etal. equation [35] and ‘‘rule of five’’ formulated by 
Lipinski [36] which established that, chemical compound could be an orally active drug in humans, if no more than one 
violation of the following rule: (i) ClogP (partition coefficient between  water  and  octanol) < 5.(ii)  Number of hydrogen 
bond donors sites ≤ 5.(iii) Number of hydrogen bond acceptors sites ≤ 10.(iv) Molecular  weight  < 500 and  molar 
refractivity should be between 40-130.   In addition, the total polar surface area (TPSA) is another key property linked to 
drug bioavailability, the passively absorbed molecules with (TPSA>140) have low oral bioavailability [37]. 
 
Table 2:  Pharmacokinetic parameters important for good oral  bioavailability of compounds 2-5: 
CPD TPSA %ABS Vol. M.wt. Logp HBD HBA V mr LogS 
3 64.63 86.70 107.25 393 2.21 1 5 0 50.49 -3.04 
Pioglitazone 68.29 85.43 171.37 356 3.29 1 5 0 55.98 -4.62 
Rosiglitazone 71.53 84.32 154.87 343 2.73 1 6 0 40.40 -3.70 
Troglitazone 84.86 79.72 197.62 441 4.94 2 6 0 40.40 -5.90 
 
TPSA: Topological Polar surface areaA°2,%ABS:Absorption percentage,Vol: Volume (A3), M.wt.:Molecular weight, Log P: Calculated lipophilicity., LogS: Solubility parameter, HBA: 
Number of hydrogen bond acceptor, HBD: Number of hydrogen bond donor,  V: Number of violation from Lipinski’s rule of five., mr: Molar Refractivity 
All calculated descriptors were performed using MOE Package [38], and their results were disclosed in (Table 2). 
Our results revealed that,  the  CLogP (factor of the lipophilicity [39]  was less than 5.0, the molecular weight (MW>  500), 
hydrogen bond acceptors (2), hydrogen bond donors (6) and molar refractivity values ranged (~40.40-50.49),this data 
showedthat,its compounds fulfill Lipinski’s rule.  
The drug-likeliness calculated (Table 2), according to (ADME-T) algorithm [40,41], which examined the ability of 
compounds for transported across the intestinal epithelium, they probably have high affinity binding to the plasma proteins, 
and may be through the blood-brain barrier, and it necessary for ability drug transported throughout the body. 
In general, No marked health effects in rodent toxicity profiles were observed,  its compound 3 the compounds can 
be used as a good oral absorption. 
2.3. Docking studies:  
The X-ray crystal structures of ALR2 have been recognized in the PDB database [42]. The analysis of the active site 
for ALR2 showed that, binding site of the ALR2 can be divided into two sub-pockets, (a) catalytic pocket (also called the 
recognition region), (b) specificity pocket. The catalytic pocket is rather stable in all the various reported crystal structures. 
In contrast, the specificity pocket can adopt different conformations, adapting itself to the size of the bound ligands via 
movement of the loop region between Cys298 and Cys303 and the different rotameric states of the surrounding amino 
acid side chains, especially of Leu300, which acting as a gate-keeper between the open and closed states. Until recently, 
only three different conformations of the specificity pocket were known, which called by Zentgraf et al [43]. The binding 
pocket conformations were exemplified by the PDB structures 1PWM, which used in this study. In order to understand the 
binding mode for protein-ligand interactions, the docking study was carried out using MOE [38]. The crystal structure of the 
human ALR2 enzyme (1PWM) complexed with (ligand Fidarestat, Figure.3)asaninhibitor,was downloaded from a protein 
data bank PDB [44].The tested compound 3 was evaluated in silico (docking), using X-ray crystal structures of ALR2  (ID: 
1PWM) [44] complexes with Fidarestat as inhibitor.  The tested compound3 docked into active sites of enzymeALR2. The 
active site of the enzyme was defined to include residues within a 10.0 Å radius to any of the inhibitor atoms. MOE scoring 
function of the most stable docking model for tested compound applied to evaluate the binding affinities between the 
inhibitors complexes with ALR2  active site (Table 3). The complexes were energy-minimized with an MMFF94 force field 
[45] until the gradient convergence 0.05 kcal/mol reached.  The most active compounds docked successfully into the 
ALR2 active site. The Dock scoring function was applied to evaluate the binding affinities between the (1PWM) and 
selected synthesized inhibitors (Rosiglitazone, Troglitazone and Pioglitazone). The (FIDand Rosiglitazone, Troglitazone 
and Pioglitazone)  werere-docked into the active site of the enzyme, and then replaced it with the tested compound in 
order to compare the binding mode of ligand, and the tested compounds. 
From (Figure3and 4; Table 3), the following results can be drawn: FID (original ligand) reveals MOE score (-81.52 
Kcal/mol) and forms 3 hydrogen bonds with: His110,  Tyr48 and Trp111, respectively, (Figure 3). Compared with (markted 
drugs) Rosiglitazone, Troglitazone and Pioglitazone, the compound (3) gives highest binding affinity with MOE score (-
149.59Kcal/mol) due to forming important interaction with His110,  Tyr48,  Trp111 and Trp110(Figure 4), otherdrug showed 
nearly binding affinity values (~ 146.34, 145.39 and 142.84) for Pioglitazone, Rosiglitazone and  Troglitazone and, 
respectively, (table 3). 
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Table3: Docking energy scores (kcal/mol) derived from the MOE for new compounds 2-5: 
Cpd. dG Int. H.B. Eele Evdw E-sol 
Fid. -81.529 0.769102 -77.706 -5.52001 -19.2262 -81.529 
Pioglitazone -146.34 -14.0453 -130.56 -6.48513 -19.7742 -24.649 
Rosiglitazone -145.39 -35.2538 -104.44 -5.10474 -11.0811 -35.846 
Troglitazone -142.84 -37.9496 -95.959 -4.71776 -22.1582 -31.954 
3 -149.59 -2.48743 -104.39 -5.57448 -4.94787 -29.165 
d.G.: free binding energy of the ligand from a given conformer, Int.: affinity binding energy of hydrogen bond  interaction 
with receptor, H.B.: Hydrogen bonding energy between protein and ligand.Eele: the electrostatic interaction with the 
receptor, Evdw: van der Waals  energies between the ligand and the receptor, E-sol.: energies between the ligand and 
the solvent for receptor. 
 
 
Figure 3: Interaction between ligand (FID) and binding site of ALR2 (1PWM, PDB code), which red dot lines represented 
hydrogen bonding interaction of ligand (Fid) with binding site. Ligand  (Fid) are represented in ball and stick mode, 
which carbon atoms are colored in dark grey, oxygen in red, nitrogen in blue and sulfur in yellow. 
 
The results obtained  clearly  reveals  that,  the  amino  acid  residues  close  to  the  reference  molecules 
Fidarestat are mostly the same as those observed in the currently synthesized compound3complex with protein (figure3 
and 4). The higher binding energies and binding process interaction observed for compound3compared with the original 
inhibitorsindicate that, this compound 3 act as inhibitor against ALR-2 and considering suitable key intermediate for 
synthesis ALR-2  inhibitorwith higher potency than marketed drug. 
  
Figure 4: Interaction between ligand 3 and binding site of ALR2 (1PWM, PDB code), which red dot lines represented 
hydrogen bonding interaction of ligands with binding site. Ligands 3 are  represented in ball and stick mode, which carbon 
atoms are colored in dark grey, oxygen in red, nitrogen in blue and sulfur in yellow.  
 
3. Conclusion 
The present work aimed to the development of novel anti-diabetes molecules containing thiazolidinedione 
pharmacophore. Systematic structure based virtual screening of the synthesized compound library, identified synthesized 
compounds as putative ALR2 binders.   The results point that, the compound 3 considers suitable inhibitor against ALR2 
than reference drug. 
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4. Experimental: 
4.1.  Instrumentation and materials: 
Melting points are uncorrected. IR spectra were recorded on a Shimadzu 440 infrared spectrophotometer (υ; cm
-1
) 
using the KBr technique (Shimadzu, Japan). NMR spectra were recorded on a Varian Gemini spectrometer (δ; ppm) 400 
MHz using TMS as internal standard. Mass spectra were recorded on a Jeol-JMS-600 mass spectrometer. Micro 
analytical data were obtained from the Micro analytical Research Centre, Faculty of Science, Cairo University. 
4.2. Synthesis: 
(E)-5-(benzo[d][1,3]dioxol-5-ylmethylene)thiazolidine-2,4-dione: 
The thiazolidinediones (1; 0.01mol) in absolute ethanol (20 mL) containing catalytic amount (0.5 gm), fused sodium 
acetatewas reacted with (1; 0.01mol)  benzodioxole carbaldehyde (0.01mol) was added. The reaction mixture was heated 
under reflux for 3h. The solid product formed was collected by filtration and recrystallized from ethanol. 
3: yellow crystals, yield 72 %, m.p. 205-07 ºC. IR (KBr, cm
-1
): 3158 (NH), and 1708, and 1628 (C=O thiazolidinone).
 1
H 
NMR (DMSO-d6) δ: 12.47(s, 1H, NH),7.57(s,1H, CHethylene),7.04-6.95 (m, 3H, aromatic), 6.01 (s, 2H, CHdioxole); 
13
C 
NMR (125 MHz) (CDCl3) δ: 167.71 and 167.22 (CO), 149.09 (C-10), 147.96 (C-9), 131.73 (C-8), 127.02 (C-13), 125.85 
(C-12), 108.94 (C-11), 108.87 (C-14), 101.93 (C-16); MS m/z (%):250 (M
+
+1, 13.22), with a base peak at 127 (100); Anal. 
Calcd for C11H7NO4S: C, 53.01; H, 2.81; N, 5.64. Found: C, 53.01; H, 2.83; N, 5.66%.  
4.3. Molecular Modelling Study: 
4.3.1. Generation of Ligand and Enzyme Structures: 
Docking study was carried out for the target compounds into (ALR2), the crystal structure of the (1PWM) complexed 
with (FID) was uploaded from the protein data bank PDB[44]. 
4.3.2. Preparation of Small Molecule: 
All electronic structure calculations were performed using the gaussian 09 program.  Geometry optimizations 
have been achieved using molecular orbital for Hartree-Fock functional theory  with a  6-311G basis sets. The structural 
parameters, such as the dipole moment of the molecules, the energy of the highest occupied molecular orbital EHOMO 
and the lowest unoccupied molecular orbital ELUMO. The  graphical  representation  of  the  molecular  electrostatic 
potential  surface  (MEP  or  ESP),  as  implemented within gaussian 09 program. 
4.3.3. MOE Stepwise 
The crystal structure of the (ALR-2) with a Fid as inhibitor molecule, was used for the receptor molecule, Water 
and inhibitor molecules were removed, and hydrogen atoms were added. The parameters and charges assigned with 
MMFF94x force field.   After alpha-site spheres were generated using the SITE FINDER module of MOE.  The optimized 
3D  structures of molecules  were  subjected  to generate different poses of  ligands  using  triangular  matcher  placement  
method, which generating poses by aligning ligand triplets of atoms on triplets of alpha spheres representing in the 
receptor site points, a random triplet of alpha sphere centers is used to determine the pose during each iteration. The pose 
generated rescored using London dG scoring function. The poses generated were refined with MMFF94x forcefield, also, 
the solvation effects were treated. The Born solvation model (GB/VI) used to calculate the final energy, and the finally 
assigned poses assigned a score based on the free energy in kcal/mol 
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Supplementary material  
Sup. Table 1: Optimized geometrical parameters of compound3 using HF with 6-311G basis set. 
Bond length  Bond Angel 
E-keto Z E-enole  E-Keto Z E-enole 
C(1) C(9) C(10) C(13) C(12) 1.376 C(10) C(9) 1.381  C(11) C(10) C(9) 120.123 O(9) C(13) C(12) 112.439 C(11) C(10) C(9) 121.741 
C(11) C(10) C(11) O(9) C(13) 1.360 C(11) C(10) 1.368  O(17) C(10) C(9) 111.699 C(14) C(13) O(9) 125.783 O(17) C(10) C(9) 109.571 
O(17) C(10) O(17) C(14) C(13) 1.379 O(17) C(10) 1.379  C(14) C(9) C(10) 121.436 O(11) C(12) C(13) 112.438 C(14) C(9) C(10) 122.612 
C(14) C(9) C(14) O(11) C(12) 1.360 C(14) C(9) 1.363  O(15) C(9) C(10) 110.983 C(17) C(12) O(11) 125.783 O(15) C(9) C(10) 109.384 
O(15) C(9) O(15) C(17) C(12) 1.379 O(15) C(9) 1.386  C(12) C(11) C(10) 117.941 C(15) C(14) C(13) 117.675 C(12) C(11) C(10) 116.602 
C(12) C(11) C(12) C(15) C(14) 1.398 C(12) C(11) 1.395  C(13) C(14) C(9) 120.396 C(16) C(17) C(12) 117.675 C(13) C(14) C(9) 117.322 
C(13) C(14) C(13) C(16) C(17) 1.398 C(13) C(14) 1.41  C(16) O(17) C(10) 107.209 C(10) O(9) C(13) 100.795 C(16) O(17) C(10) 107.866 
C(16) O(17) C(16) C(10) O(9) 1.443 C(16) O(17) 1.449  C(8) C(13) C(12) 117.529 C(8) C(16) C(15) 119.727 C(8) C(13) C(12) 116.669 
C(8) C(13) C(8) C(8) C(16) 1.337 C(8) C(13) 1.463  C(3) C(8) C(13) 133.408 C(5) C(8) C(16) 120 C(3) C(8) C(13) 132.732 
C(3) C(8) C(3) C(5) C(8) 1.337 C(3) C(8) 1.329  S(2) C(3) C(8) 129.222 S(1) C(5) C(8) 128.172 S(2) C(3) C(8) 129.849 
S(2) C(3) S(2) S(1) C(5) 1.808 S(2) C(3) 1.832  C(4) C(3) S(2) 108.286 C(4) C(5) S(1) 103.656 C(4) C(3) S(2) 108.412 
C(4) C(3) C(4) C(4) C(5) 1.523 C(4) C(3) 1.496  C(1) S(2) C(3) 96.463 C(2) S(1) C(5) 93.385 C(1) S(2) C(3) 86.68 
C(1) S(2) C(1) C(2) S(1) 1.808 C(1) S(2) 1.835  N(5) C(4) C(3) 111.006 N(3) C(4) C(5) 107.344 N(5) C(4) C(3) 113.175 
N(5) C(4) N(5) N(3) C(4) 1.465 N(5) C(4) 1.404  O(6) C(1) S(2) 121.28 O(6) C(2) S(1) 126.133 O(6) C(1) S(2) 119.359 
O(6) C(1) O(6) O(6) C(2) 1.208 O(6) C(1) 1.328  O(7) C(4) C(3) 125.838 H(22) C(14) C(13) 121.163 O(7) C(4) C(3) 123.107 
O(7) C(4) O(7) O(7) C(4) 1.208 O(7) C(4) 1.211      H(23) C(15) C(14) 119.727 H(20) C(11) C(10) 121.5 
H(20) C(11) H(20) H(22) C(14) 1.100 H(20) C(11) 1.07      H(24) C(17) C(12) 121.162 H(21) C(12) C(11) 118.657 
H(21) C(12) H(21) H(23) C(15) 1.100 H(21) C(12) 1.072      H(19) C(8) C(5) 120 H(22) C(14) C(9) 119.618 
H(22) C(14) H(22) H(24) C(17) 1.100 H(22) C(14) 1.067      H(18) N(3) C(2) 126.463 H(19) C(8) C(3) 112.661 
H(19) C(8) H(19) H(19) C(8) 1.100 H(19) C(8) 1.076      H(20) C(10) O(9) 108.426 H(23) C(16) O(15) 109.695 
H(23) C(16) H(23) H(18) N(3) 1.012 H(23) C(16) 1.073      H(21) C(10) O(9) 107.1 H(24) C(16) O(15) 109.695 
H(24) C(16) H(24) H(20) C(10) 1.113 H(24) C(16) 1.073          H(18) O(6) C(1) 117.249 
H(18) O(6) H(18) H(21) C(10) 1.113 H(18) O(6) 0.951              
 
 
Sup. Figure1. Numbering compound E-Keto and Z form according to program representing as Ball and stick. 
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 Sup. Figure2. Numbering compound E-enol according to program representing as Ball and stick. 
 
 
